Alzamend Neuro and Massachusetts General Hospital Partner on Phase II Clinical Trial for Next-Generation Lithium PTSD Treatment

6468 1 Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will lead the study as the principal investigator. A direct comparison of AL001 to a commercially available lithium carbonate product will be conducted. The study aims to compare lithium levels in the human brain and its structures to identify a potentially optimal dose of AL001 that is both safe and effective…

elong